Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled LMWH for COVID-19 Induced Hypoxemia
NCT04990830Phase 3Completed
- Sponsor
- Istanbul University
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of enoxaparin in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), hypoxemia, sponsored by Istanbul University. Started Feb 2021; status: completed.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)hypoxemia
Beyond the preview
Go deeper on NCT04990830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990830.